Innovation

Our Q2 2026 financial results

Merck’s (NYSE: MRK) Q2 2026 results reflect continued strength in oncology and animal health, plus increasing contributions from launches. Our company announced Q2 worldwide sales of $16.6 billion. “We continued to make substantial progress across our business this quarter, driven by strong execution and growing contributions from new product launches,” said Rob Davis, chairman and […]

Read more

Innovation

Our Q1 2026 financial results

Merck’s (NYSE: MRK) Q1 2026 results reflect continued strength in oncology and animal health, plus increasing contributions from launches. Our company announced Q1 worldwide sales of $16.3 billion. “We are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas,” said Rob […]

Read more

Innovation

Our Q4 and full-year 2025 financial results

Merck’s (NYSE: MRK) Q4 and full-year 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Our company announced Q4 worldwide sales of $16.4 billion. Full-year 2025 worldwide sales were $65.0 billion. “In 2025, we continued to advance leading-edge science to deliver transformative medicines and vaccines that […]

Read more